Cefoxitin

Identification

Name
Cefoxitin
Accession Number
DB01331  (EXPT00897)
Type
Small Molecule
Groups
Approved
Description

Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.

Structure
Thumb
Synonyms
  • (6R,7S)-3-[(Carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • Cefoxitin
  • Cefoxitina
  • Cefoxitine
  • Cefoxitinum
  • Ceftoxitin
  • Cephoxitin
  • CFX
  • Rephoxitin
External IDs
J01DC01
Product Ingredients
IngredientUNIICASInChI Key
Cefoxitin sodiumQ68050H03T 33564-30-6GNWUOVJNSFPWDD-XMZRARIVSA-M
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cefoxitin and DextroseInjection, solution1 g/50mLIntravenousB. Braun Medical Inc.2006-03-10Not applicableUs
Cefoxitin and DextroseInjection, solution2 g/50mLIntravenousB. Braun Medical Inc.2006-03-10Not applicableUs
Cefoxitin for InjectionPowder, for solution2 gIntramuscular; IntravenousTeva1995-12-31Not applicableCanada
Cefoxitin for InjectionPowder, for solution10 gIntramuscular; IntravenousTeva2000-01-01Not applicableCanada
Cefoxitin for InjectionPowder, for solution1 gIntramuscular; IntravenousTeva1995-12-31Not applicableCanada
Cefoxitin for Injection, USPPowder, for solution2 gIntramuscular; IntravenousHospira, Inc.2007-12-21Not applicableCanada
Cefoxitin for Injection, USPPowder, for solution1 gIntramuscular; IntravenousHospira, Inc.2007-12-21Not applicableCanada
Mefoxin Inj 1gm/vial Add-vantagPowder, for solution1 gIntravenousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1991-12-311999-08-06Canada
Mefoxin Inj 2gm/vial Add-vantagPowder, for solution2 gIntravenousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1991-12-312000-08-03Canada
Mefoxin Pws 1gm/vialPowder, for solution1 gIntramuscular; IntravenousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1987-12-312003-02-07Canada
Mefoxin Pws 2gm/vialPowder, for solution2 gIntramuscular; IntravenousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1979-12-312002-07-29Canada
Mefoxin Pws Inj 10gm/vialPowder, for solution10 gIntravenousMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1992-12-312002-07-29Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CefoxitinInjection, powder, for solution1 g/10mLIntravenousWest Ward Pharmaceutical2010-02-26Not applicableUs
CefoxitinInjection, powder, for solution100 g/1IntravenousSamson Medical Technologies Llc2016-03-01Not applicableUs
CefoxitinInjection, powder, for solution2 g/1IntravenousWG Critical Care, LLC2015-02-18Not applicableUs
CefoxitinInjection, powder, for solution2 g/1IntravenousApotex Corporation2006-02-13Not applicableUs
CefoxitinInjection, powder, for solution10 g/1IntravenousSagent Pharmaceuticals2010-08-12Not applicableUs
CefoxitinInjection, powder, for solution1 g/1IntravenousWest Ward Pharmaceutical2010-03-12Not applicableUs
CefoxitinPowder, for solution2 g/1IntravenousFresenius Kabi2011-07-06Not applicableUs
CefoxitinInjection, powder, for solution1 g/1IntravenousRemedy Repack2015-10-06Not applicableUs
CefoxitinInjection, powder, for solution1 g/1IntravenousSagent Pharmaceuticals2009-11-05Not applicableUs
CefoxitinInjection, powder, for solution10 g/1IntravenousApotex Corporation2006-02-13Not applicableUs
CefoxitinInjection, powder, for solution1 g/1IntravenousApotex Corporation2008-02-27Not applicableUs
CefoxitinInjection, powder, for solution10 g/1IntravenousWG Critical Care, LLC2013-10-01Not applicableUs
CefoxitinInjection, powder, for solution10 g/1IntravenousFresenius Kabi2012-02-21Not applicableUs
CefoxitinInjection, powder, for solution1 g/1IntravenousWG Critical Care, LLC2015-02-18Not applicableUs
CefoxitinInjection, powder, for solution2 g/1IntravenousSagent Pharmaceuticals2009-11-05Not applicableUs
CefoxitinInjection, powder, for solution2 g/1IntravenousWest Ward Pharmaceutical2010-03-12Not applicableUs
CefoxitinInjection, powder, for solution1 g/1IntravenousApotex Corporation2006-02-13Not applicableUs
CefoxitinInjection, powder, for solution2 g/1IntravenousApotex Corporation2008-02-27Not applicableUs
CefoxitinPowder, for solution1 g/1IntravenousFresenius Kabi2011-07-06Not applicableUs
MefoxinInjection, solution1 g/50mLIntravenousBioniche Pharma (Canada) Ltd2011-02-222016-03-15Us
MefoxinInjection, solution2 g/50mLIntravenousBioniche Pharma (Canada) Ltd2011-02-222016-03-15Us
Approved Over the Counter Products
Not Available
Unapproved/Other Products
Not Available
International/Other Brands
Cefoctin (Teva) / Cenomicin (Daiichi-Seiyaku) / Mefoxitin (Merck)
Brand mixtures
Not Available
Categories
UNII
6OEV9DX57Y
CAS number
35607-66-0
Weight
Average: 427.452
Monoisotopic: 427.050791293
Chemical Formula
C16H17N3O7S2
InChI Key
WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
InChI
InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1
IUPAC Name
(6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[2-(thiophen-2-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][[email protected]]12SCC(COC(N)=O)=C(N1C(=O)[[email protected]]2(NC(=O)CC1=CC=CS1)OC)C(O)=O

Pharmacology

Indication

For the treatment of serious infections caused by susceptible strains microorganisms.

Structured Indications
Pharmacodynamics

Cefoxitin is a cephamycin antibiotic often grouped with the second-generation cephalosporins. It is active against a broad range of gram-negative bacteria including anaerobes. The methoxy group in the 7a position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria.

Mechanism of action

The bactericidal action of cefoxitin results from inhibition of cell wall synthesis.

TargetActionsOrganism
AD-alanyl-D-alanine carboxypeptidase DacC
inhibitor
Escherichia coli (strain K12)
AD-alanyl-D-alanine carboxypeptidase DacA
inhibitor
Escherichia coli (strain K12)
AD-alanyl-D-alanine endopeptidase
inhibitor
Escherichia coli (strain K12)
AD-alanyl-D-alanine carboxypeptidase DacB
inhibitor
Escherichia coli (strain K12)
APenicillin-binding protein 1A
inhibitor
Escherichia coli (strain K12)
APenicillin-binding protein 1B
inhibitor
Escherichia coli (strain K12)
APeptidoglycan synthase FtsI
inhibitor
Escherichia coli (strain K12)
APenicillin-binding protein 3
inhibitor
Streptococcus pneumoniae
APenicillin-binding protein 1b
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 2a
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 1A
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 2B
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Minimal (approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period).

Route of elimination

Approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period, resulting in high urinary concentrations. Cefoxitin passes into pleural and joint fluids and is detectable in antibacterial concentrations in bile.

Half life

The half-life after an intravenous dose is 41 to 59 minutes.

Clearance
Not Available
Toxicity

The acute intravenous LD50 in the adult female mouse and rabbit was about 8.0 g/kg and greater than 1.0 g/kg, respectively. The acute intraperitoneal LD50 in the adult rat was greater than 10.0 g/kg.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcenocoumarolCefoxitin may increase the anticoagulant activities of Acenocoumarol.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Cefoxitin.Investigational
DicoumarolCefoxitin may increase the anticoagulant activities of Dicoumarol.Approved
Ethyl biscoumacetateCefoxitin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FluindioneCefoxitin may increase the anticoagulant activities of Fluindione.Investigational
PhenindioneCefoxitin may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonCefoxitin may increase the anticoagulant activities of Phenprocoumon.Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefoxitin.Approved
ProbenecidThe serum concentration of Cefoxitin can be increased when it is combined with Probenecid.Approved
WarfarinCefoxitin may increase the anticoagulant activities of Warfarin.Approved
Food Interactions
Not Available

References

Synthesis Reference

Pandurang Deshpande, Bhausaheb Khadangale, "Process for the preparation of cefoxitin." U.S. Patent US20060252928, issued November 09, 2006.

US20060252928
General References
Not Available
External Links
Human Metabolome Database
HMDB15426
KEGG Drug
D02345
KEGG Compound
C06887
PubChem Compound
441199
PubChem Substance
46505845
ChemSpider
389981
BindingDB
50335563
ChEBI
209807
ChEMBL
CHEMBL996
Therapeutic Targets Database
DAP000452
PharmGKB
PA448856
HET
CFX
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cefoxitin
ATC Codes
J01DC01 — Cefoxitin
AHFS Codes
  • 08:12.07.12
PDB Entries
FDA label
Download (76.5 KB)
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
3RecruitingTreatmentMalignant Neoplasm of Pancreas / Pancreatic Diseases1
4RecruitingNot AvailableAntibiotic Prophylaxis Surgery1
4TerminatedTreatmentUrinary Tract Infections (UTIs)1
Not AvailableNot Yet RecruitingPreventionBenign Biliary Stricture / Bile Duct Cancer Resectable / Biliary Obstructive Disease Such as Choledocholithiasis / Hilar Cholangiocarcinoma / Peri-ampullary Cancer1
Not AvailableRecruitingPreventionMaternal Infection During Pregnancy (Diagnosis) / Neonatal Infections1
Not AvailableTerminatedTreatmentAcute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntravenous1 g/10mL
Injection, powder, for solutionIntravenous1 g/1
Injection, powder, for solutionIntravenous10 g/1
Injection, powder, for solutionIntravenous100 g/1
Injection, powder, for solutionIntravenous2 g/1
Powder, for solutionIntravenous1 g/1
Powder, for solutionIntravenous2 g/1
Injection, solutionIntravenous1 g/50mL
Injection, solutionIntravenous2 g/50mL
Powder, for solutionIntramuscular; Intravenous1 g
Powder, for solutionIntramuscular; Intravenous10 g
Powder, for solutionIntramuscular; Intravenous2 g
Powder, for solutionIntravenous1 g
Powder, for solutionIntravenous2 g
Powder, for solutionIntravenous10 g
Prices
Unit descriptionCostUnit
Cefoxitin 10 gm vial112.25USD vial
Cefoxitin 2 gm vial26.28USD vial
Cefoxitin 2 gm piggyback bag22.56USD each
Cefoxitin 1 gm vial13.12USD vial
Cefoxitin 1 gm piggyback bag12.3USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)165-167Christiansen, B.G. and Firestone, R.A.; US. Patent 3,775,410; November 27, 1973; assigned Hazen, G.C.; U.S. Patent 3,780,033; December 18, 1973; assigned to Merck & Company, Inc.
logP-0.02SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.195 mg/mLALOGPS
logP0.22ALOGPS
logP0.29ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)3.59ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area148.26 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity98.76 m3·mol-1ChemAxon
Polarizability39.46 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7203
Blood Brain Barrier-0.9952
Caco-2 permeable-0.7898
P-glycoprotein substrateSubstrate0.8198
P-glycoprotein inhibitor INon-inhibitor0.8831
P-glycoprotein inhibitor IINon-inhibitor0.9715
Renal organic cation transporterNon-inhibitor0.9085
CYP450 2C9 substrateNon-substrate0.8655
CYP450 2D6 substrateNon-substrate0.8241
CYP450 3A4 substrateSubstrate0.5389
CYP450 1A2 substrateNon-inhibitor0.786
CYP450 2C9 inhibitorNon-inhibitor0.8214
CYP450 2D6 inhibitorNon-inhibitor0.8642
CYP450 2C19 inhibitorNon-inhibitor0.7954
CYP450 3A4 inhibitorNon-inhibitor0.9312
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8753
Ames testNon AMES toxic0.6912
CarcinogenicityNon-carcinogens0.9329
BiodegradationNot ready biodegradable0.979
Rat acute toxicity1.6623 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9951
hERG inhibition (predictor II)Non-inhibitor0.8518
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted LC-MS/MS Spectrum - 10V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 10V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, NegativePredicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cephalosporin 3'-carbamates. These are cephalosporins that are substituted at the 3'-position by a carbamate group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactams
Sub Class
Beta lactams
Direct Parent
Cephalosporin 3'-carbamates
Alternative Parents
Cephamycins / N-acyl-alpha amino acids and derivatives / 1,3-thiazines / Thiophenes / Tertiary carboxylic acid amides / Carbamate esters / Heteroaromatic compounds / Secondary carboxylic acid amides / Azetidines / Organic carbonic acids and derivatives
show 10 more
Substituents
Cephalosporin 3'-carbamate / Cephamycin / N-acyl-alpha amino acid or derivatives / Alpha-amino acid or derivatives / Meta-thiazine / Heteroaromatic compound / Carbamic acid ester / Thiophene / Tertiary carboxylic acid amide / Azetidine
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cephalosporin, semisynthetic derivative, cephamycin (CHEBI:209807 )

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Removes C-terminal D-alanyl residues from sugar-peptide cell wall precursors.
Gene Name
dacC
Uniprot ID
P08506
Uniprot Name
D-alanyl-D-alanine carboxypeptidase DacC
Molecular Weight
43608.595 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [PubMed:368000 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Removes C-terminal D-alanyl residues from sugar-peptide cell wall precursors.
Gene Name
dacA
Uniprot ID
P0AEB2
Uniprot Name
D-alanyl-D-alanine carboxypeptidase DacA
Molecular Weight
44443.62 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [PubMed:368000 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Cell wall formation. May play a specialized role in remodeling the cell wall. Specifically hydrolyzes the DD-diaminopimelate-alanine bonds in high-molecular-mass murein sacculi.
Gene Name
pbpG
Uniprot ID
P0AFI5
Uniprot Name
D-alanyl-D-alanine endopeptidase
Molecular Weight
33887.085 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [PubMed:368000 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Not involved in transpeptidation but exclusively catalyzes a DD-carboxypeptidase and DD-endopeptidase reaction.
Gene Name
dacB
Uniprot ID
P24228
Uniprot Name
D-alanyl-D-alanine carboxypeptidase DacB
Molecular Weight
51797.85 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [PubMed:368000 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
Gene Name
mrcA
Uniprot ID
P02918
Uniprot Name
Penicillin-binding protein 1A
Molecular Weight
93635.545 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [PubMed:368000 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
Gene Name
mrcB
Uniprot ID
P02919
Uniprot Name
Penicillin-binding protein 1B
Molecular Weight
94291.875 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [PubMed:368000 ]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Peptidoglycan glycosyltransferase activity
Specific Function
Essential cell division protein that is required for the synthesis of peptidoglycan at the division septum (PubMed:1103132, PubMed:9614966). Catalyzes the synthesis of cross-linked peptidoglycan fr...
Gene Name
ftsI
Uniprot ID
P0AD68
Uniprot Name
Peptidoglycan synthase FtsI
Molecular Weight
63876.925 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [PubMed:368000 ]
Kind
Protein
Organism
Streptococcus pneumoniae
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Not Available
Gene Name
pbp3
Uniprot ID
Q75Y35
Uniprot Name
Penicillin-binding protein 3
Molecular Weight
45209.84 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring acyl groups
Specific Function
Not Available
Gene Name
pbp1b
Uniprot ID
Q7CRA4
Uniprot Name
Penicillin-binding protein 1b
Molecular Weight
89479.92 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring acyl groups
Specific Function
Not Available
Gene Name
pbp2a
Uniprot ID
Q8DNB6
Uniprot Name
Penicillin-binding protein 2a
Molecular Weight
80797.94 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Penicillin binding
Specific Function
Cell wall formation.
Gene Name
pbpA
Uniprot ID
Q8DR59
Uniprot Name
Penicillin-binding protein 1A
Molecular Weight
79700.9 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Not Available
Specific Function
Penicillin binding
Gene Name
penA
Uniprot ID
P0A3M6
Uniprot Name
Penicillin-binding protein 2B
Molecular Weight
73872.305 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]

Enzymes

Kind
Protein
Organism
Bacillus licheniformis
Pharmacological action
Unknown
Actions
Substrate
General Function
Beta-lactamase activity
Specific Function
Not Available
Gene Name
penP
Uniprot ID
P00808
Uniprot Name
Beta-lactamase
Molecular Weight
33995.36 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Song W, Lee KM, Kim HS, Kim JS, Kim J, Jeong SH, Roh KH: Clonal spread of both oxyimino-cephalosporin- and cefoxitin-resistant Klebsiella pneumoniae isolates co-producing SHV-2a and DHA-1 beta-lactamase at a burns intensive care unit. Int J Antimicrob Agents. 2006 Dec;28(6):520-4. Epub 2006 Nov 13. [PubMed:17095195 ]
  4. d'Azevedo PA, Goncalves AL, Musskopf MI, Ramos CG, Dias CA: Laboratory tests in the detection of extended spectrum beta-lactamase production: National Committee for Clinical Laboratory Standards (NCCLS) screening test, the E-test, the double disk confirmatory test, and cefoxitin susceptibility testing. Braz J Infect Dis. 2004 Oct;8(5):372-7. Epub 2005 Mar 17. [PubMed:15798813 ]
  5. Ke YY, Lin TH: A theoretical study on the activation of Ser70 in the acylation mechanism of cephalosporin antibiotics. Biophys Chem. 2005 Apr 22;114(2-3):103-13. Epub 2004 Nov 30. [PubMed:15829343 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:38